Patent classifications
A61K31/35
Targeting a non-canonical notch signaling pathway for cancer treatment
Methods and compositions are provided for treating an individual having cancer. Aspects of the methods include administering to the individual an inhibitor of a non-canonical Notch signaling pathway gene in an amount effective to treat the cancer. Also provided are reagents, devices and kits thereof that find use in practicing the subject methods.
Targeting a non-canonical notch signaling pathway for cancer treatment
Methods and compositions are provided for treating an individual having cancer. Aspects of the methods include administering to the individual an inhibitor of a non-canonical Notch signaling pathway gene in an amount effective to treat the cancer. Also provided are reagents, devices and kits thereof that find use in practicing the subject methods.
Cannabis extracts and methods of preparing and using same
The invention relates to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance (BDS) for incorporation in to a medicament. It also relates to a BDS, for use in pharmaceutical formulations. In particular it relates to BDS comprising cannabinoids obtained by extraction from cannabis.
Gold (I)-Phosphine Compounds as Anti-Bacterial Agents
A compound of formula (I): for use in the prevention or treatment of a bacterial infection wherein: A is either S or Se; RA is selected from: wherein: each of Y.sup.1, Y.sup.2, Y.sup.3, Y.sup.4 and Y.sup.9 is independently selected from CH or N, wherein at least three of Y.sup.1, Y.sup.2, Y.sup.3, Y.sup.4 and Y.sup.9 is CH; V is selected from O, CH—OR.sup.01, N—CO.sub.2—R.sup.C2 or N—R.sup.N2; one of Y.sup.5, Y.sup.6, Y.sup.7 and Y.sup.8 is selected from CH and N, and the others are CH; X is selected from NH, S or O; R.sup.C1 is selected from O—R.sup.O2 or NHR.sup.N1; R.sup.O1 is selected from H and C.sub.1-3 unbranched alkyl; R.sup.O2 is C.sub.1-3 unbranched alkyl; R.sup.N1 is selected from H and C.sub.1-3 unbranched alkyl; R.sup.N2 is C.sub.1-3 unbranched alkyl; R.sup.C2 is either C.sub.1-3 unbranched alkyl or C.sub.3-4 branched alkyl; R.sup.C3 is selected from C.sub.1-3 unbranched alkyl and C.sub.2H.sub.4CO.sub.2H; R.sup.C4 is either H or Me; R.sup.C5 is either H or Me; R.sup.C6 represents one or two optional methyl substituents; and n is an integer from 2 to 8.
##STR00001##
ANTIVIRAL EFFECTS OF NARASIN IN SWINE FEED
The present invention relates to a composition for ameliorating viral infections in nursery pigs. The composition contains the polyether ionophore narasin, and is supplied to the nursery pigs in an orally-acceptable form. The composition is effective in reducing viral shedding and the severity of diarrhea after challenge of nursery pigs with Porcine Epidemic Diarrhea Virus (PEDV).
ANTIVIRAL EFFECTS OF NARASIN IN SWINE FEED
The present invention relates to a composition for ameliorating viral infections in nursery pigs. The composition contains the polyether ionophore narasin, and is supplied to the nursery pigs in an orally-acceptable form. The composition is effective in reducing viral shedding and the severity of diarrhea after challenge of nursery pigs with Porcine Epidemic Diarrhea Virus (PEDV).
Methods and compositions for attenuating allergenicity in protein products
The invention relates to a low sugar or sugar free concentrated polyphenolic extract comprising at least about 30% polyphenols (w/w) and a protein-polyphenol aggregate matrix comprising at least about 15% polyphenols (w/w). The invention further relates to methods of producing a low sugar or sugar free concentrated polyphenolic extract comprising (a) extracting a low sugar or sugar free plant tissue with an aqueous solvent to produce an extract having an aqueous portion and a solids portion; (b) filtering the extract to separate the aqueous portion from the solids portion; and (c) reducing the volume of the separated aqueous portion, and methods of producing a protein-polyphenol aggregate matrix comprising about 1% to about 40% polyphenols (w/w) using the low sugar or sugar free concentrated polyphenolic extract of the invention.
Methods and compositions for attenuating allergenicity in protein products
The invention relates to a low sugar or sugar free concentrated polyphenolic extract comprising at least about 30% polyphenols (w/w) and a protein-polyphenol aggregate matrix comprising at least about 15% polyphenols (w/w). The invention further relates to methods of producing a low sugar or sugar free concentrated polyphenolic extract comprising (a) extracting a low sugar or sugar free plant tissue with an aqueous solvent to produce an extract having an aqueous portion and a solids portion; (b) filtering the extract to separate the aqueous portion from the solids portion; and (c) reducing the volume of the separated aqueous portion, and methods of producing a protein-polyphenol aggregate matrix comprising about 1% to about 40% polyphenols (w/w) using the low sugar or sugar free concentrated polyphenolic extract of the invention.
SMALL MOLECULE ANTI-SCARRING AGENTS
Disclosed are methods of treating fibrosis in a patient in need thereof that includes administering to the patient an amount of an active agent, as identified herein, that is therapeutically effective to inhibit myofibroblast formation and thereby treat the fibrosis. Also disclosed is a recombinant cell line that includes a recombinant gene that expresses a detectable expression product in a dose-dependent response to TGFβ, as well as methods of identifying a compound that inhibits TGFβ-mediated expression of the detectable expression product.
SMALL MOLECULE ANTI-SCARRING AGENTS
Disclosed are methods of treating fibrosis in a patient in need thereof that includes administering to the patient an amount of an active agent, as identified herein, that is therapeutically effective to inhibit myofibroblast formation and thereby treat the fibrosis. Also disclosed is a recombinant cell line that includes a recombinant gene that expresses a detectable expression product in a dose-dependent response to TGFβ, as well as methods of identifying a compound that inhibits TGFβ-mediated expression of the detectable expression product.